Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials


SV2A Marker of Synaptogenesis in a Clinical Trial of Psilocybin for Depression


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT05601648

Organisation Name: Washington University School of Medicine

Overal Status: Withdrawn

Start Date: July 1, 2023

Last Update: January 30, 2023

Lead Sponsor: Washington University School of Medicine

Brief Summary: Participants with depression will be given a single dose of psilocybin and supportive psychotherapy before, during, and after drug administration. Participants will undergo positron emission tomography (PET) imaging before and one week after psilocybin using a marker of synaptic density. This design allows us to assess the relationship between neurotrophic, and antidepressant effects produced by psilocybin.

Conditions:
  • Major Depressive Disorder
  • Anhedonia


Total execution time in seconds: 0.29030609130859